Selank (TP-7)
Selank | TP-7
Mechanism of Action
Selank 11mg contains the same selank heptapeptide as the 10mg product — a synthetic derivative of tuftsin with anxiolytic, nootropic, and immunomodulatory properties. The mechanism involves GABA-A receptor modulation, enkephalin-degrading enzyme inhibition, and BDNF expression enhancement. See the Selank 10mg entry for comprehensive research details.
The 11mg vial provides slightly more material than the 10mg version, offering flexibility for research protocols that require marginally larger quantities per vial.
Key Research Findings
- Seredenin et al. (1998) showed selank produces anxiolytic effects comparable to benzodiazepines without sedation.
- Kost et al. (2001) demonstrated selank inhibits enkephalin-degrading enzymes, potentially enhancing endogenous opioid activity.
- Zozulya et al. (2008) showed selank modulates IL-6 and T-helper cell balance.
References
Dosage in Research
Intranasal doses of 250-500 mcg/day in Russian clinical studies. Animal studies: 100-300 mcg/kg.
Storage & Handling
Store lyophilized powder at -20C. Reconstituted solution at 2-8C, use within 14-21 days.
Frequently Asked Questions
How does the 11mg differ from the 10mg Selank?
Same compound, slightly different quantity per vial. Choose based on your protocol requirements.
Source Selank (TP-7) for your research
98%+ purity, third-party tested, COA included